Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI) used in the management of Attention Deficit Hyperactivity Disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention span, hyperactivity, emotional...
- Mechanism
- Curator reviewed · 3 references
Atomoxetine is known to be a potent and selective inhibitor of the norepinephrine transporter (NET), which prevents cellular reuptake of norepinephrine throughout the brain, which is thought to improve the symptoms of ADHD. More recently, positron emission tomography (PET) imaging studies in rhesus monkeys have shown that atomoxetine also binds to the serotonin transporter (SERT), and blocks the N-methyl-d-aspartate (NMDA) receptor, indicating a role for the glutamatergic system in the pathophysiology of ADHD.
- Primary indication
- Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.Curator reviewed · 1 structured indication
- Formula / weight
- C17H21NO · 255.3547 g/mol (avg)
- First approval
- Canada, 2004 · United States, 2002
- Also known as
- Tomoxetine
- Brand names
Resolves to
VHGCDTVCOLNTBX-QGZVFWFLSA-NSMILESCNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Atomoxetine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account